Feature Articles

1. Stabilization Of Cell-Free RNA In Plasma For Noninvasive Diagnosis And Prognosis
   8/18/2010
   The discovery of the presence of cell-free nucleic acids in blood By M. R. Fernando, S. Norton and W. L. Ryan, Streck, Inc.
2. Ropack Now Offering Stickpack Capabilities In Low RH And Temperature-Controlled Environment
   8/10/2010
   Ropack, a leader in innovative packaging solutions for the pharmaceutical, biopharmaceutical and nutraceutical industries, now provides the technology and expertise for stickpack packaging of solid oral dosage in a low relative humidity and temperature-controlled environment. By Ropack, Inc.
3. Collaboration Enables Faster Time To Market
   8/5/2010
   Whether generic or branded, in the high-stakes race to bring a therapeutic drug to market, manufacturers are engaged in two simultaneous challenges. By Herman Mitchell
4. Assessing Patient Recruitment Location To Improve Trial Performance
   8/5/2010
   Innovation, cost-effective processes, and emerging markets are probably three of the most common topics being discussed in the pharmaceutical and biopharmaceutical markets today. By Dan Schell
5. Only Time Will Tell With Biotech QbD
   8/5/2010
   When manufacturing a pharmaceutical product, there are various attributes that contribute to overall quality, including solubility, toxicity, and uniformity. By James Netterwald, Ph.D.
6. A New Breed Of Generics Company
   8/5/2010
   I admit it — I was skeptical of the claims Alvogen was making. Prior to typing a single word on this two-year-old generics company, I encountered claims such as "creating the pharmaceutical company of tomorrow … ," "a radical new business model … ," and "Alvogen will be one of the world's 10 biggest generic drugmakers by revenues in five years." By Dan Schell
7. SaaS Model Turns LIMS Paradigm On Its Head
   7/29/2010
   The massive spending of big pharma in the 1980s and 1990s took a big hit with the recession. Outsourcing and downsizing became the life sciences norm, and internal IT departments were among the first to go. For many organizations, this move particularly hurt the laboratory and its reliance on IT to help maintain in-house laboratory information management systems (LIMS). By Cindy Dubin
8. CMO PAT Implementation: Time For Strategic Decisions
   7/23/2010
   Process analytical technology (PAT) is a vital step towards a future where continuous manufacturing and real time product release can become real in the pharmaceutical sector. After a slow start, PAT is high on the agenda for Big Pharma. But it is not so common among contract manufacturers (CMOs). By Rebecca Vangenechten
9. Continuous Manufacturing For Secondary Processes: Leapfrog Time?
   7/23/2010
   Pharmaceutical secondary manufacturing has long stood in stark contrast to the drug discovery end of the business, as well as to other sectors, when it comes to innovation such as continuous manufacturing. By Rebecca Vangenechten and Ivo Backx
10. High-Content Imaging Detection Of Cellular Lipids To Measure Lipid Toxicity And Cell Differentiation
    7/9/2010
    The detection and understanding of prelethal mechanisms in toxicological profiling and compound screening are important components of drug discovery. Cationic amphiphilic drugs can impact lipid metabolism and inhibit the normal phospholipid metabolism resulting in their intracellular accumulation (phospholipidosis). By Life Science Research - Cellomics

First 1 2 3 4 5 6 7 8 9 10 10 (Last)